Occupational Therapists in Paw Paw, MI Accepting Medicare

6 Occupational Therapists found. Showing 1 - 6

Alexis Kelly, OTR-L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 801 Hazen St, Paw Paw, MI 49079 Phone: 269-655-3334    Fax: 269-657-6523

Mrs. Megan Schreur, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 451 Health Pkwy Fl 1, Paw Paw, MI 49079 Phone: 269-657-1490

Mrs. Fawn Michelle Stender, OTRL Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 801 Hazen Street, Suite C, Paw Paw, MI 49079 Phone: 269-657-5574    Fax: 269-657-3474

Ms. Britt Deanne Kirchinger, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 801 Hazen Street, Suite C, Paw Paw, MI 49079 Phone: 269-657-5574    Fax: 269-657-3474

Cesar Carrizales, PA Occupational Therapist Medicare: Medicare Enrolled Practice Location: 451 Health Pkwy Ste G, Paw Paw, MI 49079 Phone: 269-668-3348

Aubrie Frantz, MS, OTR/L, CLT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 451 Health Pkwy, Paw Paw, MI 49079 Phone: 269-657-1490

News Archive

TCAR procedure offers potentially safer method for high-risk stroke patients

The carotid arteries supply oxygenated blood to the brain. Every year, more than 300,000 people in the United States are diagnosed with blockages, or plaques, in their carotid artery. When these arteries become blocked due to plaque build-up, an individual is at high risk for a stroke if the plaque ruptures and flows to the brain.

Scientists imitate the Human Blood-retinal barrier on a microfluidic chip

For years scientists have sought to minimise Animal testing and speed up clinical trials. One alternative is the use of in vitro assays using live cells, but its effectiveness is limited, since it is difficult to reproduce interaction and interconnection between cells.

Simple blood test may provide early detection of cancer

A simple blood test is being developed by researchers at Ben-Gurion University of the Negev (BGU) and Soroka University Medical Center in Beer-Sheva, Israel that may provide early detection of many types of cancer.

Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.

House Ways and Means committee passes bill to prohibit genetic discrimination

The House Ways and Means Committee on Wednesday by voice vote unanimously approved a bill (HR 493) that would ban discrimination against U.S. residents based on the results of genetic tests, CongressDaily reports.

Read more Medical News

› Verified 8 days ago